|
Gene: IQCH |
Gene summary for IQCH |
Gene summary. |
Gene information | Species | Human | Gene symbol | IQCH | Gene ID | 64799 |
Gene name | IQ motif containing H | |
Gene Alias | NYDSP5 | |
Cytomap | 15q23 | |
Gene Type | protein-coding | GO ID | GO:0008150 | UniProtAcc | A0A024R5X4 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
64799 | IQCH | S014 | Human | Liver | HCC | 1.61e-20 | 6.56e-01 | 0.2254 |
64799 | IQCH | S015 | Human | Liver | HCC | 8.54e-29 | 8.44e-01 | 0.2375 |
64799 | IQCH | S016 | Human | Liver | HCC | 1.20e-26 | 6.95e-01 | 0.2243 |
64799 | IQCH | S028 | Human | Liver | HCC | 4.70e-02 | 1.52e-01 | 0.2503 |
64799 | IQCH | S029 | Human | Liver | HCC | 7.27e-03 | 1.96e-01 | 0.2581 |
Page: 1 |
Transcriptomic changes along malignancy continuum. |
Tissue | Expression Dynamics | Abbreviation |
Liver | HCC: Hepatocellular carcinoma | |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Stomach | WIM | |
Stomach | SIM | |
Liver | NAFLD | |
Liver | Cirrhotic | |
Liver | HCC |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
IQCH | SNV | Missense_Mutation | novel | c.2825N>C | p.Leu942Ser | p.L942S | Q86VS3 | protein_coding | deleterious(0) | probably_damaging(0.98) | TCGA-A2-A0D4-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
IQCH | SNV | Missense_Mutation | c.251N>T | p.Thr84Ile | p.T84I | Q86VS3 | protein_coding | tolerated(0.18) | benign(0.037) | TCGA-A8-A07R-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Ancillary | zoledronic | SD | |
IQCH | SNV | Missense_Mutation | c.749N>A | p.Arg250Lys | p.R250K | Q86VS3 | protein_coding | tolerated(0.79) | benign(0) | TCGA-BH-A0AY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | SD | ||
IQCH | SNV | Missense_Mutation | c.2489N>A | p.Ser830Asn | p.S830N | Q86VS3 | protein_coding | tolerated(0.57) | benign(0.005) | TCGA-D8-A1J8-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | nolvadex | SD | |
IQCH | SNV | Missense_Mutation | rs146418351 | c.1985N>A | p.Arg662Gln | p.R662Q | Q86VS3 | protein_coding | deleterious(0.01) | benign(0.001) | TCGA-D8-A27G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
IQCH | insertion | Nonsense_Mutation | novel | c.804_805insTTGCATTCTCTTCTGGCACCCTGATTAGATCAGAAAGGGATA | p.Tyr268_Asp269insLeuHisSerLeuLeuAlaProTerLeuAspGlnLysGlyIle | p.Y268_D269insLHSLLAP*LDQKGI | Q86VS3 | protein_coding | TCGA-A8-A092-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | CR | ||
IQCH | insertion | Frame_Shift_Ins | novel | c.1421_1422insTCTT | p.Gln474HisfsTer11 | p.Q474Hfs*11 | Q86VS3 | protein_coding | TCGA-BH-A0AY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | SD | |||
IQCH | insertion | Nonsense_Mutation | novel | c.1422_1423insTGCTTTCACACTTGCATAAGTAATTAAAGCCTGGTTAC | p.Asn475CysfsTer9 | p.N475Cfs*9 | Q86VS3 | protein_coding | TCGA-BH-A0AY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | SD | |||
IQCH | SNV | Missense_Mutation | c.667C>T | p.Pro223Ser | p.P223S | Q86VS3 | protein_coding | tolerated(0.54) | benign(0.007) | TCGA-C5-A1BQ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | cisplatin | CR | |
IQCH | SNV | Missense_Mutation | c.313N>G | p.Gln105Glu | p.Q105E | Q86VS3 | protein_coding | tolerated(1) | benign(0.062) | TCGA-C5-A1MK-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | carboplatin | PD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |